Aspire Biopharma Holdings, Inc., early-stage biopharmaceutical company, engages in developing and marketing of disruptive technology for delivery mechanisms for do no harm drugs in the United States. The company is headquartered in Humacao, Puerto Rico.
| Revenue (TTM) | 6,200 |
| Gross Profit (TTM) | -116 |
| EBITDA | — |
| Operating Margin | -375045.00% |
| Return on Equity | 0.00% |
| Return on Assets | -1657.00% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $-1.80 |
| Price-to-Book | — |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | 0 |
| Float | $4.36M |
| % Insiders | 0.00% |
| % Institutions | 0.00% |